When will the HELIDAC patents expire, and when will generic HELIDAC be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Casper Pharma Llc	HELIDAC	bismuth subsalicylate; metronidazole; tetracycline hydrochloride	TABLET, CHEWABLE, TABLET, CAPSULE;ORAL	050719-001	Aug 15, 1996		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: April 25, 2026

HELIDAC: Investment Scenario and Fundamentals Analysis

What is HELIDAC and what does it treat?

HELIDAC is a branded, fixed-dose Helicobacter pylori eradication regimen marketed in several countries (the brand name is used for combinations of an antibiotic plus an acid suppression component). The core commercial proposition is H. pylori eradication in the settings where clinicians use guideline-based triple and/or optimized eradication regimens.

Clinical use pattern

Indication class: H. pylori eradication in peptic ulcer disease and related dyspepsia pathways where eradication is indicated.
Typical positioning: first-line eradication regimens, often in “triple therapy” or “quadruple-like” combinations depending on local labeling and availability.

Commercial implication

Market demand is driven by diagnosis rates, adherence to eradication guidelines, and regimen tolerability.
Pricing power depends on competitive landscape (generics, alternative branded regimens, and local hospital formularies).

What is the patent and regulatory risk profile?

A drug’s investment case for HELIDAC depends on whether the marketed product is still under composition-of-matter, formulation, or method-of-treatment protection in each key geography. For H. pylori therapies, the typical risk profile is rapid generic erosion because the active pharmaceutical ingredients are long-established and routinely go off-patent.

Investment-relevant patent risk drivers (H. pylori class)

High generic penetration risk after expiry of core APIs and combination patents.
Short effective exclusivity windows when the brand relies on incremental formulation rather than broad claims.
Market-by-market status: some territories grant supplementary protections; others do not.

Regulatory risk drivers

Bioequivalence requirements for generics.
Label changes over time (resistance guidance, recommended durations, and local resistance thresholds) that can reduce brand relevance if the brand’s label becomes less aligned with current practice.

How big is the addressable market and what drives volume?

The addressable market for HELIDAC is tied to the prevalence of H. pylori infection and the share of diagnosed patients who receive eradication therapy.

Demand drivers

Diagnosis and testing rates (urea breath test, stool antigen, endoscopy biopsy pathways).
Guideline adherence for confirmed infection.
Treatment-line mix: initial eradication vs rescue therapies.
Antibiotic resistance dynamics (region-specific resistance shifts that can change regimen selection and duration).

Revenue sensitivity

Erosion risk is usually front-loaded once generics enter.
Sales are sensitive to:
- payer reimbursement and hospital tender outcomes,
- pack sizes and clinician prescribing preferences,
- switching costs relative to alternate brands and generics.

What are the competitive fundamentals?

H. pylori eradication regimens compete on efficacy, tolerability, dosing convenience, and total cost of therapy.

Competitive dimensions that decide share

Resistance-adjusted regimen performance: local clarithromycin resistance can push prescribers away from clarithromycin-based combinations.
Adherence: fixed-dose combinations can support adherence, but pill burden and duration still affect compliance.
Safety and tolerability: antibiotic-associated adverse events drive switching.
Price and access: hospital formularies and national reimbursement policies often dominate uptake.

Typical competitive structure

Branded originators face generic multiples within a short time horizon.
Surviving differentiated products rely on:
- better tolerability profiles,
- dosing simplification,
- alignment with updated guideline resistance frameworks,
- local exclusivity or supply advantages.

What is the investment case logic if exclusivity is limited?

If HELIDAC’s competitive moat is mostly commercial (not patent-based), the investment case becomes a lifecycle-execution model.

Fundamentals that still support value

Geography and channel leverage: strong distribution in markets where generics are slower to penetrate due to tendering structures.
Brand localization: established prescriber habits and patient familiarity.
Supply reliability: consistent availability can matter in eradication therapy where course completion is essential.

Where the case breaks

Generic substitution that undercuts price materially while maintaining comparable clinical outcomes.
Guideline mismatch if recommended regimens shift away from the active combination used in HELIDAC.
Regulatory label changes in target markets that reduce clinical preference.

What due-diligence checkpoints should an investor run?

A rigorous HELIDAC fundamentals screen should map product protection and future cash flow durability against generic and guideline risk.

Patent and protection mapping (per key market)

Composition-of-matter status for each API.
Combination-specific patents and method-of-treatment claims.
Any supplementary protections (where applicable): pediatric extensions, SPC-like protection frameworks, or regulatory exclusivities.
Legal and opposition history: claim scope and sustained validity in relevant jurisdictions.

Regulatory and label durability

Current label indications and recommended treatment duration.
Resistance guidance and whether the regimen remains consistent with local standards.
Pharmacovigilance signals that could force label restriction.

Commercial KPIs

Channel share in institutional vs retail segments.
Tender pricing trends and time-to-substitution after generic launch.
Net sales composition: volume vs price vs rebate structure.

Production and supply

Supply chain robustness for fixed-dose regimens.
Batch-level quality consistency and regulator inspection outcomes.

What are the base-case, bull-case, and bear-case scenarios?

Base case (typical for H. pylori brands post-early exclusivity)

Revenue growth is flat-to-low as generics pressure price.
Share becomes dependent on local access dynamics and prescriber inertia.
Profitability is maintained if manufacturing economics and access terms offset price erosion.

Bull case (outperformance requires at least one durable lever)

Delayed generic entry in targeted geographies due to protection stack strength or procedural barriers.
Product retains guideline relevance and is still preferred in empiric or confirmation-based pathways.
Strong institutional penetration with stable tender pricing.

Bear case (value destruction path)

Rapid generic substitution at scale with large price cuts.
Label or guideline shift reduces the regimen’s clinical preference.
Margin compression exceeds cost offsets due to competitive bidding.

How should an investor value HELIDAC at the fundamental level?

A HELIDAC valuation framework should treat the brand as a time-limited cash flow asset with clear “event risk” around generic launches and protection expiry.

Cash flow drivers

Peak sales (if still under exclusivity in some markets) and then:
- price erosion rate post-entry,
- volume retention rate after generic substitution,
- gross margin after competitive tender dynamics,
- working capital and rebate intensity.

Discounting logic

Model a falling revenue curve anchored to expected generic timing and competitive intensities.
Use scenario-specific probability weights around:
- protection durability,
- guideline alignment,
- tender outcomes.

Operational levers

Portfolio rationalization, pack and dosing optimization, and targeted country expansion where competition is less intense.

Key Takeaways

HELIDAC is an H. pylori eradication brand whose investment fundamentals are dominated by generic substitution risk and local guideline alignment.
The investment case hinges on market-by-market protection status, label durability, and access through institutional channels.
Valuation should be event-driven: generic entry timing and price erosion rates are the primary determinants, with margins supported only if supply economics and tender economics hold.
Bull outcomes require durable protection in key geographies or sustained clinical preference consistent with resistance-adjusted guideline practice.

FAQs

Is HELIDAC likely to face generic competition?
Yes. H. pylori regimen markets typically experience rapid generic penetration once core protections and combination rights expire, driving price compression.
What determines whether HELIDAC keeps market share?
Local institutional access (tenders/formularies), dosing convenience and adherence, and continued guideline relevance given regional resistance patterns.
What is the biggest valuation risk?
The timing of generic entry in key markets and the speed of price erosion after substitution.
How do guideline shifts affect HELIDAC’s future sales?
If clinical standards shift away from the specific combination used in HELIDAC, prescribing preference can decline even before generic entry.
What diligence matters most for underwriting?
Per-market patent/protection status, current label and duration recommendations, tender and pricing history, and evidence of sustained institutional demand.

References

[1] PubMed. Helicobacter pylori eradication therapy guideline documents and resistance-related therapy reviews. (Accessed via PubMed search results).
[2] European Medicines Agency (EMA). H. pylori medicinal product information and procedural documents for fixed-dose eradication regimens.
[3] U.S. FDA. Drug label data and generic/bioequivalence framework references for fixed-dose oral antibiotic and acid suppression combinations.
[4] World Gastroenterology Organisation (WGO). Global guideline materials on Helicobacter pylori diagnosis and treatment and regional resistance considerations.

HELIDAC Drug Patent Profile

Which patents cover Helidac, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for HELIDAC

US Patents and Regulatory Information for HELIDAC

HELIDAC Market Analysis and Financial Projection